Asprosin-neutralizing antibodies as a treatment for metabolic syndrome

BACKGROUND: Recently, we discovered a new glucogenic and centrally acting orexigenic hormone – asprosin. Asprosin is elevated in metabolic syndrome (MS) patients, and its genetic loss results in reduced appetite, leanness, and blood glucose burden, leading to protection from MS. METHODS: We generate...

Descripción completa

Detalles Bibliográficos
Autores principales: Mishra, Ila, Duerrschmid, Clemens, Ku, Zhiqiang, He, Yang, Xie, Wei, Silva, Elizabeth Sabath, Hoffman, Jennifer, Xin, Wei, Zhang, Ningyan, Xu, Yong, An, Zhiqiang, Chopra, Atul R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102062/
https://www.ncbi.nlm.nih.gov/pubmed/33904407
http://dx.doi.org/10.7554/eLife.63784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102062/
https://www.ncbi.nlm.nih.gov/pubmed/33904407
http://dx.doi.org/10.7554/eLife.63784

Ejemplares similares